Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

David Zurakowski, Ph.D.

Co-Author

This page shows the publications co-authored by David Zurakowski and Matthew Warman.
Connection Strength

0.815
  1. Causal somatic mutations in urine DNA from persons with the CLOVES subgroup of the PIK3CA-related overgrowth spectrum. Clin Genet. 2018 05; 93(5):1075-1080.
    View in: PubMed
    Score: 0.194
  2. Induced superficial chondrocyte death reduces catabolic cartilage damage in murine posttraumatic osteoarthritis. J Clin Invest. 2016 08 01; 126(8):2893-902.
    View in: PubMed
    Score: 0.175
  3. Enhanced Wnt signaling improves bone mass and strength, but not brittleness, in the Col1a1(+/mov13) mouse model of type I Osteogenesis Imperfecta. Bone. 2016 09; 90:127-32.
    View in: PubMed
    Score: 0.174
  4. Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta. J Bone Miner Res. 2014 Oct; 29(10):2297-306.
    View in: PubMed
    Score: 0.154
  5. Lubricin restoration in a mouse model of congenital deficiency. Arthritis Rheumatol. 2015 Nov; 67(11):3070-81.
    View in: PubMed
    Score: 0.042
  6. Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA. J Pediatr. 2015 Apr; 166(4):1048-54.e1-5.
    View in: PubMed
    Score: 0.040
  7. PIK3CA activating mutations in facial infiltrating lipomatosis. Plast Reconstr Surg. 2014 Jan; 133(1):12e-19e.
    View in: PubMed
    Score: 0.037
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.